Date | Price Target | Rating | Analyst |
---|---|---|---|
11/3/2023 | $6.00 → $2.00 | Outperform → Sector Perform | RBC Capital Mkts |
4/28/2023 | $5.00 → $1.50 | Neutral → Underperform | BofA Securities |
2/27/2023 | $16.00 | Neutral → Outperform | Wedbush |
1/6/2023 | $8.00 → $5.00 | Buy → Neutral | BofA Securities |
6/13/2022 | $5.00 | Neutral | Wedbush |
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm
CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa
10-Q - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)
Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone payments, plus tiered royalties on net sales. Reported Pfizer's announcement of positive topline results from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo is co-developing with and licensing to Pfizer. Continue to amass encouraging safety and efficacy data from the Phase 1/2 STAAR study of isaralgagene civaparvovec for F
Agreement leverages Sangamo's proprietary capsid delivery platform and epigenetic regulation capabilities to address certain neurodegenerative diseases Sangamo expected to receive $50 million in near-term upfront license fees and milestone payments and is eligible to earn up to $1.9 billion in development and commercial milestone payments across multiple medicines, as well as tiered royalties on net sales Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced it has entered into a license agreement with Genentech, a member of the Roche Group, to develop intravenously administered genomic medicines to treat certain neurodegenerative diseases. Sangamo has
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close on Tuesday, August 6, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, August 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with t
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)
RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously
BofA Securities downgraded Sangamo Therapeutics from Neutral to Underperform and set a new price target of $1.50 from $5.00 previously
Wedbush upgraded Sangamo Therapeutics from Neutral to Outperform and set a new price target of $16.00
Announced global epigenetic regulation and capsid delivery license agreement with Genentech to develop novel genomic medicines for neurodegenerative diseases. Expect to receive $50 million in near-term upfront license fees and milestone payments and eligible to earn up to $1.9 billion in milestone payments, plus tiered royalties on net sales. Reported Pfizer's announcement of positive topline results from Phase 3 AFFINE trial evaluating giroctocogene fitelparvovec, an investigational Hemophilia A gene therapy that Sangamo is co-developing with and licensing to Pfizer. Continue to amass encouraging safety and efficacy data from the Phase 1/2 STAAR study of isaralgagene civaparvovec for F
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its second quarter 2024 financial results after the market close on Tuesday, August 6, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Tuesday, August 6, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with t
Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today that the company has scheduled the release of its first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, May 9, which will be open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the numbe
HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $5 price target.
U.S. stocks traded lower toward the end of trading, with the S&P 500 falling around 100 points on Wednesday. The Dow traded down 0.82% to 40,025.48 while the NASDAQ fell 2.92% to 17,472.06. The S&P 500 also fell, dropping, 1.84% to 5,453.67. Check This Out: Jim Cramer Calls Axsome A ‘Double Or Nothing Stock,’ Says SAP Is ‘Incredible’ Leading and Lagging SectorsUtilities shares jumped by 0.8% on Wednesday. In trading on Wednesday, consumer discretionary shares fell by 3%. Top Headline Shares of AT&T Inc. (NYSE:T) rose around 5% during Wednesday’s session following second-quarter earnings. AT&T reported fiscal second-quarter 2024 operating revenues of $29.8 billion, down
Shares of General Dynamics Corporation (NYSE:GD) fell sharply during Wednesday's session after the company reported worse-than-expected second-quarter EPS results. Revenue for the quarter increased 18% year-over-year to $11.976 billion, beating the consensus of $11.438 billion. EPS of $3.26 (up 20.7% YoY) missed the consensus of $3.29, according to data from Benzinga Pro. General Dynamics shares declined 5.2% to $279.26 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers NuZee, Inc. (NASDAQ:NUZE) jumped 192% to $3.01. Dermata Therapeutics, Inc. (NASDAQ:DRMA) rose 142.4% to $3.0799 after falling over 22% on Tuesday. Selina Hospitality PLC